Pfizer faces legal action from Australian competition regulator

SYDNEY Thu Feb 13, 2014 3:27am EST

The Pfizer logo is seen outside their world headquarters in New York November 5, 2013. REUTERS/Adam Hunger

The Pfizer logo is seen outside their world headquarters in New York November 5, 2013.

Credit: Reuters/Adam Hunger

Related Topics

SYDNEY (Reuters) - Australia's competition regulator said on Thursday it was taking legal action against the local division of Pfizer Inc over the way it marketed its cholesterol-lowering drug Lipitor to pharmacies.

The Australian Competition and Consumer Commision (AC) said Pfizer had, to deter competition, offered pharmacies "significant" discounts and rebates if they stocked at least a year's worth of the drug, which goes by the generic name atorvastatin and is prescribed to over one million Australians.

The drug had generated annual sales exceeding A$700 million ($632.35 million) for Pfizer in Australia before the company's patent expired in there in May 2012, the ACCC said.

Pfizer denied its methods were uncompetitive.

"Pfizer believes strongly that the offers referred to by the ACCC were competitive. We will vigorously defend the proceedings," the company said in a statement.

The ACCC said a preliminary hearing against the company was scheduled for March 18 at the Federal Court of Australia. ($1 = 1.1070 Australian dollars)

(Reporting by Colin Packham; Editing by Miral Fahmy)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
dualcitizen wrote:
Pfizer, lilly, merck, none of them have any ethics, only comply with regs cause of penalties not ethics.

Feb 13, 2014 9:50am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.